Pulmatrix Inc. (PULM) shares were falling -17.05% to trade at $1.07 in the current market at the last check. PULM stock closed the previous session at $1.29. The PULM stock volume remained 3.44 million shares, which was higher than the average daily volume of 3.02 million shares within the past 50 days. PULM shares have fallen by -3.01% over the last 12 months
What is recently happening in PulmatrixInc?
Today, the biopharmaceutical company, Pulmatrix, Inc. (PULM) has announced that it will withdraw the portfolio of narrow spectrum kinase inhibitor (NSKI) from Johsnon& Johnson. This news came in due to Johnson & Johnson’s enterprise innovation’s decision to forfeit Pulmatrix’s license, development, and commercialization agreement.
The NSKI portfolio also contained PUR1800, the development of which the company has stated it will seek to continue. The development will be done with ongoing clinical and toxicology studies which will allow the programs in acute exacerbations in COPD (AECOPD) and other chronic airway diseases to be supported.
Pulamtrix’s continuance of PUR1800 program
PULM stock has created a new updated strategy for the PUR1800 program;
Initially, the current progress is that 28-day toxicology studies have been completed that showed PUR1800 to have improved and stable chemical and physical structure with a reduced potential of drug’s accumulation in the lung. Study has also demonstrated dose proportional systemic exposure and potential for it to be stable for long-term dosing as compared to RV162 (predecessor drug).
Phase 1b clinical study of PUR1800 in AECOPD is ongoing along with dosing. The objective includes finding the safety, tolerability, and exploratory biomarkers for assisting in the demonstration of target engagement and anti-inflammatory effect. The topline data is expected to be gathered in the 4th quarter of 2021.
PUR1800’s phase 2b test for proof-of-concept efficacy is to be initiated for the treatment of AECOP in this year. Pulmatrix also has an ongoing toxicology study for long term which will be data from 6-9 months. This will help explore the chronic dosing paradigms and potential where non-steroidal and inti-inflammatory treatment can be of benefit.
Why PUR1800 program is good for PULM stock
The CEO of PULM stock, Ted Raad stated that the phase 2b study of AECOPD has a peak-net revenue potential in US of total $2.5 billion. He furthers comments that the combination of iSPERSE along with progress in PUR1800 has an opportunity to address new paradigms of treating steroid resistant and infection driven inflammations related to lung-conditions.
Insight on the product offerings and background of PULM stock
PULM stock is about a company based on biopharmaceuticals that focuses on the development of treatments and therapies using innovative and unique approach to its design and creation. The company specifically focuses on addressing pulmonary and non-pulmonary diseases. PULM stock does this through inhaled-specific therapies using their own flagship technology – iSPERSETM.
iSPERSETM is the proprietary and patented engineered dry powder delivery platform on which all of the candidates for Pulmatrix are based upon. This dry powder platform is specifically chosen for its improved and efficient therapeutic delivery to the lungs as well as reduced side-effects and maximizing local concentrations. All of this improves the overall pulmonary and non-pulmonary health and treatment of the patients.
Another of the company’s proprietary product pipeline includes treatment of lung-related serious diseases as well as neurologic disorders. This includes bronchopulmonary aspergillosis (ABPA), lung cancers and migraines.